Peptide Database

CRITICAL NOTICE: All peptide compounds listed below are strictly for laboratory research, in vitro, and academic testing purposes only. Under no circumstances are these products intended for human or veterinary diagnostic, therapeutic, or clinical use.

Peptide Research Reference Database

Quick-reference tool for chemical profiles, target mechanisms, and molecular weights.

Showing 40 of 40 Peptides

BPC-157

Tissue Repair

A partial sequence of human gastric juice protein studied heavily for its potent tissue-protective and regenerative capabilities in tendons, ligaments, and gut lining.

Mol. Weight: 1419.5 g/mol Target/Mechanism: Angiogenesis, VEGFR2 upregulation, growth factor modulation Typical Research Concentration: 250 - 500 mcg daily (subcutaneous/oral)

Citation: Chang, C-H., et al. "BPC-157 accelerates tendon healing." J Orthop Res, 2011.

TB-500 (Thymosin Beta-4)

Tissue Repair

A synthetic fraction of Thymosin Beta-4 that promotes cellular migration, angiogenesis, and rapid wound repair by binding actin.

Mol. Weight: 4963.5 g/mol Target/Mechanism: G-actin sequestration, cell migration, tissue regeneration Typical Research Concentration: 2.0 - 5.0 mg twice weekly (subcutaneous)

Citation: Philp, D., et al. "Thymosin beta4 promotes angiogenesis and wound healing." Kidney Int, 1999.

Keywords: semaglutide ozempic wegovy glp1 glp-1 receptor agonist blood sugar weight management satiety insulin

Semaglutide

Metabolic

A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion, slows gastric emptying, and significantly reduces appetite.

Mol. Weight: 4113.4 g/mol Target/Mechanism: GLP-1 receptor activation, pancreatic beta cell stimulation Typical Research Concentration: 0.25 - 2.4 mg weekly (subcutaneous)

Citation: Wilding, J. P. H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med, 2021.

Tirzepatide

Metabolic

A dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist studied for highly potent metabolic and blood sugar regulation.

Mol. Weight: 4813.5 g/mol Target/Mechanism: Dual GIP and GLP-1 receptor activation, synergistic lipolysis Typical Research Concentration: 2.5 - 15.0 mg weekly (subcutaneous)

Citation: Jastreboff, A. M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med, 2022.

Retatrutide

Metabolic

An experimental triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors to maximize fat oxidation and energy expenditure.

Mol. Weight: 4731.3 g/mol Target/Mechanism: GIP, GLP-1, and Glucagon triple receptor activation Typical Research Concentration: 0.5 - 12.0 mg weekly (subcutaneous)

Citation: Jastreboff, A. M., et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." N Engl J Med, 2023.

CJC-1295 (No DAC / Mod GRF 1-29)

GH Secretagogue

A modified version of GHRH (Growth Hormone Releasing Hormone) that stimulates pulsatile release of natural growth hormone without spike side effects.

Mol. Weight: 3367.9 g/mol Target/Mechanism: GHRH receptor agonist, pituitary stimulation Typical Research Concentration: 100 - 300 mcg daily (subcutaneous)

Citation: Teichman, S. L., et al. "Prolonged stimulation of growth hormone by CJC-1295." Clin Endocrinol, 2006.

CJC-1295 with DAC

GH Secretagogue

Features a Drug Affinity Complex (DAC) that binds to blood albumin, drastically extending the peptide's metabolic half-life to several days.

Mol. Weight: 3647.2 g/mol Target/Mechanism: Long-acting GHRH agonist, sustained GH/IGF-1 elevation Typical Research Concentration: 1.0 - 2.0 mg weekly (subcutaneous)

Citation: Jette, L., et al. "Human growth hormone-releasing factor analog CJC-1295 conjugates with albumin." Bioconjug Chem, 2005.

Ipamorelin

GH Secretagogue

Highly selective Growth Hormone Secretagogue (GHS) that releases GH without significantly increasing appetite, cortisol, or prolactin.

Mol. Weight: 711.9 g/mol Target/Mechanism: Ghrelin receptor agonist, pulsatile growth hormone release Typical Research Concentration: 200 - 300 mcg daily (subcutaneous)

Citation: Raun, K., et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Pharmacol, 1998.

Sermorelin

GH Secretagogue

A 29-amino acid truncated analog of growth hormone-releasing hormone (GHRH) studied for pediatric and age-management GH stimulation.

Mol. Weight: 3357.9 g/mol Target/Mechanism: GHRH receptor stimulation, physiological GH pulsatility Typical Research Concentration: 250 - 500 mcg nightly (subcutaneous)

Citation: Walker, R. F. "Sermorelin: A clinical review of its use in GH deficiency." Clin Interv Aging, 2006.

GHK-Cu (Copper Peptide)

Aesthetic / Skin

A naturally occurring copper-binding tripeptide studied for systemic wound healing, collagen synthesis, and dramatic skin anti-aging profiles.

Mol. Weight: 340.5 g/mol (free peptide) Target/Mechanism: Collagen/elastin upregulation, stem cell activation, anti-inflammatory Typical Research Concentration: 1% - 2% Topical / 2.0 - 5.0 mg daily (subcutaneous)

Citation: Pickart, L., et al. "GHK-Cu as a regenerative tissue remodeling peptide." Int J Mol Sci, 2018.

PT-141 (Bremelanotide)

Neurology / Mood

A synthetic melanocortin receptor agonist (primarily MC3R/MC4R) that acts on the central nervous system to treat sexual dysfunction in laboratory models.

Mol. Weight: 1025.2 g/mol Target/Mechanism: Melanocortin receptor agonist, central nervous system activation Typical Research Concentration: 1.0 - 2.0 mg as needed (subcutaneous)

Citation: Diamond, L. E., et al. "Efficacy of bremelanotide in models of sexual dysfunction." Urology, 2006.

MOTS-c

Metabolic

A mitochondrial-derived peptide that regulates metabolic homeostasis, acts as an exercise mimetic, and counters diet-induced insulin resistance.

Mol. Weight: 2174.6 g/mol Target/Mechanism: AMPK activation, cellular glucose uptake, mitochondrial biogenesis Typical Research Concentration: 5.0 - 10.0 mg 2-3x weekly (subcutaneous)

Citation: Lee, C., et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis." Cell Metab, 2015.

Tesamorelin

GH Secretagogue

A synthetic growth hormone-releasing hormone (GHRH) analog specifically cleared/studied for the reduction of visceral abdominal fat.

Mol. Weight: 5135.9 g/mol Target/Mechanism: GHRH receptor activation, pituitary GH release, lipolysis Typical Research Concentration: 1.0 - 2.0 mg daily (subcutaneous)

Citation: Falutz, J., et al. "Effects of Tesamorelin on Visceral Fat in HIV Patients." N Engl J Med, 2007.

Epitalon (Epithalon)

Longevity

A synthetic tetrapeptide resembling epithalamin (pineal gland secretion) studied for telomerase activation and cellular lifespan extension in animal models.

Mol. Weight: 390.4 g/mol Target/Mechanism: Telomerase upregulation, melatonin production, chromatin structure restoration Typical Research Concentration: 5.0 - 10.0 mg daily in 10-day courses (subcutaneous)

Citation: Anisimov, V. N., et al. "Epitalon decelerates aging and suppresses carcinogenesis in mice." Ann N Y Acad Sci, 2001.

Melanotan II

Aesthetic / Skin

A synthetic melanocortin receptor agonist that stimulates eumelanin production (skin tanning) and increases libido in laboratory models.

Mol. Weight: 1024.2 g/mol Target/Mechanism: Non-selective MC1R, MC3R, MC4R, and MC5R receptor agonist Typical Research Concentration: 250 - 500 mcg daily (subcutaneous)

Citation: Dorr, R. T., et al. "Evaluation of Melanotan II for tanning and libido." Life Sci, 1996.

Selank

Neurology / Mood

A synthetic heptapeptide derived from tuftsin, researched as an anxiolytic (anti-anxiety agent) that stabilizes cognitive performance without sedation.

Mol. Weight: 751.9 g/mol Target/Mechanism: GABAergic modulation, enkephalinase inhibition, BDNF stimulation Typical Research Concentration: 250 - 500 mcg daily (nasal spray / subcutaneous)

Citation: Antonova, L. V., et al. "Anxiolytic effects of Selank in neuro-psychological disorders." Neurosci Behav Physiol, 2010.

Semax

Neurology / Mood

An analog of adrenocorticotropic hormone (ACTH 4-10) studied for neurogenesis, neuroprotective properties, memory retention, and ADHD research.

Mol. Weight: 812.9 g/mol Target/Mechanism: BDNF upregulation, trkB activation, neurotransmitter modulation Typical Research Concentration: 200 - 600 mcg daily (nasal spray / subcutaneous)

Citation: Gusev, E. I., et al. "Neuroprotective effects of Semax in acute stroke." Cerebrovasc Dis, 2005.

DSIP (Delta Sleep-Inducing Peptide)

Neurology / Mood

A naturally occurring nonapeptide that crosses the blood-brain barrier and promotes deep slow-wave (delta) sleep architecture.

Mol. Weight: 848.8 g/mol Target/Mechanism: GABAergic pathways, stress response attenuation, endocrine sleep-cycles Typical Research Concentration: 100 - 250 mcg pre-sleep (subcutaneous)

Citation: Schoenenberger, G. A., et al. "Characterization of delta sleep-inducing peptide." Proc Natl Acad Sci, 1977.

Kisspeptin-10

Longevity

A powerful hormone regulator playing a core role in triggering GnRH, LH, and FSH release, studied in infertility and hypogonadism.

Mol. Weight: 1302.4 g/mol Target/Mechanism: GPR54 (Kiss1R) agonist, hypothalamic-pituitary-gonadal axis activation Typical Research Concentration: 100 - 200 mcg daily (subcutaneous)

Citation: Dhillo, W. S., et al. "Kisspeptin-10 stimulates gonadotropin release in humans." J Clin Endocrinol Metab, 2005.

KPV

Tissue Repair

A tripeptide derivative of alpha-MSH studied for extreme anti-inflammatory pathways, inflammatory bowel disease (IBD) relief, and skin recovery.

Mol. Weight: 385.5 g/mol Target/Mechanism: NF-kB suppression, mast cell stabilizing, melanocortin pathway Typical Research Concentration: 200 - 500 mcg daily (oral/subcutaneous)

Citation: Kannengiesser, K., et al. "KPV reduces gut inflammation in acute colitis." Inflamm Bowel Dis, 2008.

ARA-290 (Cibinetide)

Tissue Repair

A non-erythropoietin erythropoietin receptor agonist explored for treating neuropathic pain, sarcopenia, and peripheral nerve injury.

Mol. Weight: 1251.4 g/mol Target/Mechanism: Innate repair receptor (IRR) activation, pro-inflammatory cytokine inhibition Typical Research Concentration: 4.0 - 8.0 mg daily (subcutaneous)

Citation: Brines, M., et al. "ARA 290 relieves neuropathic pain in sarcoidosis." Mol Med, 2014.

PEG-MGF

Tissue Repair

Pegylated Mechano Growth Factor that localizes muscle cell repair, activates muscle stem cells (satellite cells), and boosts hypertrophy.

Mol. Weight: 2867.2 g/mol (excluding PEG) Target/Mechanism: IGF-1Ec splice variant signaling, satellite cell activation Typical Research Concentration: 200 - 400 mcg twice weekly (subcutaneous)

Citation: Goldspink, G., et al. "Mechano Growth Factor (MGF) in local tissue repair." J Physiol, 2005.

IGF-1 LR3

Tissue Repair

A highly potent, long-acting analog of insulin-like growth factor-1 that triggers extreme skeletal muscle protein synthesis and hyperplasia.

Mol. Weight: 9111.1 g/mol Target/Mechanism: IGF-1 receptor activation, PI3K-Akt/mTOR pathway Typical Research Concentration: 20 - 50 mcg daily (subcutaneous)

Citation: Tomas, F. M., et al. "Increased potency of IGF-1 LR3 in animal growth models." J Endocrinol, 1993.

Hexarelin

GH Secretagogue

A potent growth hormone-releasing hexapeptide with strong cytoprotective and recovery-promoting properties in cardiovascular models.

Mol. Weight: 887.0 g/mol Target/Mechanism: CD36 receptor binding, ghrelin receptor stimulation, systemic GH spike Typical Research Concentration: 100 - 200 mcg daily (subcutaneous)

Citation: Imbimbo, B. P., et al. "Growth hormone release by Hexarelin." Eur J Clin Pharmacol, 1994.

GHRP-2

GH Secretagogue

Growth Hormone Releasing Peptide-2 acts directly on the pituitary to stimulate physiological pulses of human growth hormone.

Mol. Weight: 817.9 g/mol Target/Mechanism: GHS-R (ghrelin receptor) agonist, moderate cortisol/prolactin elevation Typical Research Concentration: 100 - 150 mcg daily (subcutaneous)

Citation: Bowers, C. Y., et al. "Structure-activity relationships of GHRP-2." Endocrinology, 1992.

GHRP-6

GH Secretagogue

An analog of ghrelin that stimulates robust GH release alongside dramatic appetite stimulation and gastrointestinal motility.

Mol. Weight: 873.0 g/mol Target/Mechanism: Ghrelin receptor agonist, AMPK signaling in hypothalamus Typical Research Concentration: 100 - 300 mcg daily (subcutaneous)

Citation: Popovic, V., et al. "Stimulation of growth hormone by GHRP-6." Lancet, 1990.

HGH Fragment 176-191

Metabolic

A small fragment of the C-terminus of human growth hormone that isolates lipid-burning mechanisms without raising blood sugar levels.

Mol. Weight: 1817.1 g/mol Target/Mechanism: Beta-3 adrenergic receptor stimulation, lipolysis activation Typical Research Concentration: 250 - 500 mcg daily (subcutaneous)

Citation: Ng, F. M., et al. "The lipolytic domain of human growth hormone (176-191)." Endocrine, 2000.

AOD-9604

Metabolic

A modified analog of HGH fragment 177-191 designed to actively stimulate fat loss and cartilage regeneration without glycemic impact.

Mol. Weight: 1815.1 g/mol Target/Mechanism: Lipolysis stimulation, lipogenesis inhibition, cartilage repair Typical Research Concentration: 250 - 500 mcg daily (subcutaneous)

Citation: Heffernan, M., et al. "The effects of human GH drug fragment AOD-9604 on obesity." Int J Obes, 2001.

Thymosin Alpha-1 (TA-1)

Longevity

A naturally occurring thymic peptide studied extensively for restoration of immune function, T-cell maturation, and defense against chronic infections.

Mol. Weight: 3108.3 g/mol Target/Mechanism: Toll-like receptor signaling, NK and CD8+ cell upregulation Typical Research Concentration: 1.5 mg twice weekly (subcutaneous)

Citation: Garaci, E., et al. "Thymosin alpha1 in combination therapy for chronic viral infections." Ann N Y Acad Sci, 2007.

SS-31 (Elamipretide)

Longevity

A mitochondrial-targeted peptide that stabilizes cardiolipin, boosts ATP output, and reduces harmful reactive oxygen species (ROS) in age models.

Mol. Weight: 639.8 g/mol Target/Mechanism: Cardiolipin binding, inner mitochondrial membrane protection Typical Research Concentration: 10.0 - 40.0 mg daily (subcutaneous)

Citation: Szeto, H. H., et al. "Mitochondrial-targeted peptide SS-31 prevents oxidative damage." J Pharmacol Exp Ther, 2011.

FoxO4-DRI

Longevity

A cell-permeable senolytic peptide designed to interfere with FoxO4-p53 binding, triggering selective apoptosis (cell death) in senescent cells.

Mol. Weight: 5360.2 g/mol Target/Mechanism: Senescent cell clearance, p53 signaling restoration Typical Research Concentration: 1.0 - 5.0 mg/kg of research model mass

Citation: Baar, M. P., et al. "Targeted clearance of senescent cells restores tissue homeostasis." Cell, 2017.

Oxytocin

Neurology / Mood

A critical mammalian peptide hormone that acts as a central neurotransmitter, heavily researched for social bonding, mood, and autism models.

Mol. Weight: 1007.2 g/mol Target/Mechanism: Oxytocin receptor activation, cortisol reduction Typical Research Concentration: 10 - 40 mcg daily (intranasal)

Citation: Heinrichs, M., et al. "Social support and oxytocin interact to suppress cortisol." Biol Psychiatry, 2003.

Cerebrolysin

Neurology / Mood

A purified peptide mixture derived from porcine brain proteins, containing neurotrophic factors studied for cognitive recovery and dementia research.

Mol. Weight: Complex mixture (< 10,000 g/mol) Target/Mechanism: Neurotrophic support, BDNF/NGF mimetic pathways Typical Research Concentration: 5.0 - 10.0 mL daily (intramuscular / IV infusion)

Citation: Ruether, E., et al. "Efficacy of Cerebrolysin in Alzheimer's disease." Pharmacopsychiatry, 2001.

Pinealon

Longevity

A synthetic tripeptide developed to restore function in pineal gland cell lines and balance circadian sleep-wake cycles.

Mol. Weight: 398.4 g/mol Target/Mechanism: Melatonin pathway restoration, brain cell protein synthesis Typical Research Concentration: 1.0 - 2.0 mg daily (subcutaneous/oral)

Citation: Khavinson, V. H., et al. "Pinealon protects brain neurons from oxidative stress." Bull Exp Biol Med, 2011.

VIP (Vasoactive Intestinal Peptide)

Tissue Repair

An immunomodulatory, vasodilating hormone researched for treating lung fibrosis, severe asthma, and intestinal barrier dysfunctions.

Mol. Weight: 3325.8 g/mol Target/Mechanism: VPAC1 and VPAC2 receptor binding, anti-inflammatory cytokine release Typical Research Concentration: 100 - 200 mcg daily (subcutaneous/nasal)

Citation: Pozo, D., et al. "VIP as a therapeutic agent in autoimmune diseases." Trends Immunol, 2003.

Gonadorelin

Longevity

A synthetic gonadotropin-releasing hormone (GnRH) used to study direct stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Mol. Weight: 1182.3 g/mol Target/Mechanism: GnRH receptor agonist, pituitary hormone release Typical Research Concentration: 100 - 200 mcg as needed (subcutaneous)

Citation: Mortimer, C. H., et al. "Gonadorelin for pituitary function evaluation." Br Med J, 1974.

LL-37 (Cathelicidin)

Tissue Repair

An antimicrobial host-defense peptide with robust bactericidal, wound-healing, and skin barrier-protecting properties.

Mol. Weight: 4493.3 g/mol Target/Mechanism: Cell membrane permeabilization, immune cell chemotaxis Typical Research Concentration: 100 - 500 mcg topical/subcutaneous

Citation: Heilborn, J. D., et al. "The antimicrobial peptide LL-37 is critical for wound healing." J Invest Dermatol, 2003.

Humanin

Longevity

A mitochondrial-derived cytoprotective peptide that prevents apoptosis (cell death) in neural, vascular, and cardiac tissue lines.

Mol. Weight: 2689.3 g/mol Target/Mechanism: Bax protein binding, GP130 receptor interaction, cellular survival promotion Typical Research Concentration: 1.0 - 5.0 mg daily (subcutaneous)

Citation: Hashimoto, Y., et al. "Humanin: A novel neuroprotective factor." J Neurosci, 2001.

Follistatin-344

Tissue Repair

A glycoprotein that acts as a potent myostatin inhibitor, researched for massive increases in skeletal muscle mass and muscular dystrophy therapy.

Mol. Weight: ~37,800 g/mol Target/Mechanism: Myostatin and activin-A binding/neutralization Typical Research Concentration: 100 mcg daily for 10-day cycles (subcutaneous)

Citation: Haidet, A. M., et al. "Follistatin-344 increases muscle mass in animal models." PNAS, 2008.

Argireline (Acetyl Hexapeptide-8)

Aesthetic / Skin

A cosmetic peptide modeled after the SNAP-25 protein, studied for relaxing facial muscles to reduce the depth of mechanical expression wrinkles.

Mol. Weight: 888.9 g/mol Target/Mechanism: SNARE complex destabilization, inhibition of catecholamine release Typical Research Concentration: 5% - 10% concentration in topical formulations

Citation: Blanes-Mira, C., et al. "A synthetic hexapeptide (Argireline) with antiwrinkle activity." Int J Cosmet Sci, 2002.

DoD Dietary Supplement Ingredient Checker

Notice for Service Members: This lookup tool references major high-risk, prohibited compounds. You must always cross-reference your product labels directly with the official, live OPSS Prohibited List.

    No prohibited matches found in this index.

    Important Safety Reminder: Just because an ingredient does not show up here does not mean it is safe or approved. The DoD prohibits all controlled substances, prescription medications, and unapproved drugs hidden in dietary supplements. Always inspect labels for proprietary blends and look for third-party testing seals (like NSF Certified for Sport or Informed Choice).

    Need to search the complete, live military database of over 800+ substances?

    Open Official OPSS Database →